Spots Global Cancer Trial Database for pirtobrutinib
Every month we try and update this database with for pirtobrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients | NCT06263491 | Mantle Cell Lym... | Rituximab Pirtobrutinib | 18 Years - | M.D. Anderson Cancer Center | |
| Pirtobrutinib With Rituximab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma | NCT06390956 | Marginal Zone L... | Biopsy Biospecimen Col... Computed Tomogr... Pirtobrutinib Positron Emissi... Rituximab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | NCT05317936 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | NCT05536349 | Leukemia | Pirtobrutinib Obinutuzumab Venetoclax Valacyclovir Allopurinol | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | NCT05024045 | Leukemia, Lymph... Lymphoma, B-cel... Lymphoma, Non-H... Multiple Myelom... B-cell Lymphoma Waldenstrom Mac... Lymphoma, Mantl... | LOXO-338 Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | NCT05172700 | Leukemia, Lymph... Lymphoma, Lymph... Lymphoma, Mantl... Waldenstrom Mac... Ritcher's Trans... | Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | NCT05990465 | Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Burkitt Lymphom... | Pirtobrutinib LV20.19 CAR T c... | 18 Years - 81 Years | Medical College of Wisconsin | |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | NCT06252675 | Mantle Cell Lym... | Obinutuzumab Glofitamab Pirtobrutinib Tumor Imaging Biospecimen Col... ClonoSeq Assay Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company | |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | NCT05317936 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | NCT06333262 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Obinutuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | NCT06333262 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Obinutuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | NCT06252675 | Mantle Cell Lym... | Obinutuzumab Glofitamab Pirtobrutinib Tumor Imaging Biospecimen Col... ClonoSeq Assay Bone Marrow Bio... | 18 Years - | University of California, San Francisco | |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | NCT04965493 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05254743 | Chronic Lymphoc... Leukemia, Lymph... Leukemia, B-cel... Small Lymphocyt... | Pirtobrutinib Ibrutinib | 18 Years - | Eli Lilly and Company | |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | NCT05536349 | Leukemia | Pirtobrutinib Obinutuzumab Venetoclax Valacyclovir Allopurinol | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
